Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

PMID:
30478421
2.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

3.

Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.

Oncotarget. 2017 Jan 10;8(2):3724-3745. doi: 10.18632/oncotarget.12554. Review.

4.

Role of androgen receptor splice variants in prostate cancer metastasis.

Xu J, Qiu Y.

Asian J Urol. 2016 Oct;3(4):177-184. doi: 10.1016/j.ajur.2016.08.003. Epub 2016 Aug 20.

5.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

6.

Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.

Chattopadhyay I, Wang J, Qin M, Gao L, Holtz R, Vessella RL, Leach RW, Gelman IH.

Oncotarget. 2017 Feb 7;8(6):10324-10347. doi: 10.18632/oncotarget.14401.

7.

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.

Crona DJ, Whang YE.

Cancers (Basel). 2017 Jun 12;9(6). pii: E67. doi: 10.3390/cancers9060067. Review.

8.

NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Yu C, Wu G, Li R, Gao L, Yang F, Zhao Y, Zhang J, Zhang R, Zhang J, Yao L, Yuan J, Li X.

Cancer Biol Ther. 2015;16(2):287-96. doi: 10.1080/15384047.2014.1002348.

9.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

10.

Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Coarfa C, Fiskus W, Eedunuri VK, Rajapakshe K, Foley C, Chew SA, Shah SS, Geng C, Shou J, Mohamed JS, O'Malley BW, Mitsiades N.

Oncogene. 2016 May 5;35(18):2345-56. doi: 10.1038/onc.2015.295. Epub 2015 Sep 14.

11.

YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.

Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B.

Nat Commun. 2015 Sep 1;6:8126. doi: 10.1038/ncomms9126.

12.

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.

Cao B, Qi Y, Yang Y, Liu X, Xu D, Guo W, Zhan Y, Xiong Z, Zhang A, Wang AR, Fu X, Zhang H, Zhao L, Gu J, Dong Y.

PLoS One. 2014 Nov 6;9(11):e111201. doi: 10.1371/journal.pone.0111201. eCollection 2014.

13.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

14.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

15.

Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.

Tilki D, Schaeffer EM, Evans CP.

Eur Urol Focus. 2016 Dec;2(5):499-505. doi: 10.1016/j.euf.2016.11.013. Epub 2016 Dec 9. Review.

16.

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.

To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA.

Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007.

PMID:
29398263
17.

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.

Luo J.

Asian J Androl. 2016 Jul-Aug;18(4):580-5. doi: 10.4103/1008-682X.178490. Review.

18.

Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ.

Eur Urol. 2015 Jan;67(1):53-60. doi: 10.1016/j.eururo.2014.05.005. Epub 2014 May 29.

19.

Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F.

Neoplasia. 2013 Jul;15(7):761-72.

20.

Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.

Maughan BL, Antonarakis ES.

Curr Treat Options Oncol. 2015 Dec;16(12):57. doi: 10.1007/s11864-015-0375-z.

PMID:
26537882

Supplemental Content

Support Center